KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma

Yong Kim(National Institutes of Health), Javed Khan(Kent State University), Xinyu Wen(National Institutes of Health), Jason R. Evans, Nadya I. Tarasova(National Institutes of Health), Joshua T. Kowalczyk(National Institutes of Health), Lisa M. Jenkins(National Institutes of Health), Silvia Pomella(University of Rome Tor Vergata), Ranuka Sinniah(National Institutes of Health), James B. McMahon(National Cancer Institute), Robert G. Hawley(George Washington University), Jane Jones(Protein Express (United States)), Jun S. Wei(Center for Cancer Research), Abdalla Abdelmaksoud(National Cancer Institute), Joseph J. Barchi(Frederick National Laboratory for Cancer Research), Raj Chari(National Institutes of Health), Benjamin Z. Stanton(Nationwide Children's Hospital), Lauren Procter(Protein Express (United States)), John S. Schneekloth(National Cancer Institute), Megan L. Peach(Frederick National Laboratory for Cancer Research), Vineela Gangalapudi(National Cancer Institute), Barry R. O’Keefe(Target (United States)), Girma M. Woldemichael(Division of Undergraduate Education), David Milewski(National Cancer Institute), Dominic Esposito(Leidos (United States)), Hsien-Chao Chou(National Cancer Institute), Young Song(University of British Columbia), Berkley E. Gryder(University School), Chaoyu Wang(Cancer Genetics (United States)), Shilpa R. Shenoy(Target (United States)), Maura O’Neill(Protein Express (United States)), Jack F. Shern(National Institutes of Health)
Nature Communications
February 24, 2024
Cited by 19


Related Papers